BIOLOGICAL MARKERS IN TREATMENT OF PROSTATE CANCER

治疗前列腺癌的生物标志物

• 批准号: 3556295
• 负责人: Tsann Ming Chu
• 金额: $ 6.54万
• 依托单位: ROSWELL PARK CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-06-01 至 1986-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556295
• 关键词: acid phosphatase; alkaline phosphatase; blood banks; enzyme linked immunosorbent assay; gel electrophoresis; high performance liquid chromatography; human subject; immunochemistry; immunoelectrophoresis; isozymes; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer immunodiagnosis; prostate neoplasms; serology /serodiagnosis; spectrometry; tumor antigens

The objective of this proposal is to continue to provide research and laboratory core support to the Cooperative Clinical Trials of the National Cancer Institute's National Prostatic Cancer Project. For purpose of quality control, it is imperative for the various participating centers to have uniform biological markers, relevant to monitoring the efficacy of prostate cancer treatment and management, in various treatment protocols. An objective clinical pathological evaluation can be performed effectively in a cooperative group only from a standard set of tests and data. The evaluation will be carried out from clinical information compiled at the Central Statistics Office of the group, and from multiple laboratory tests, as provided by this proposal, that are not readily available in participating hospitals locally or routinely. Serum prostate-specific antigen, prostatic acid phosphatase, bone isoenzyme and liver isoenzyme of alkaline phosphatase will be measured. Any new biomarkers or assay procedures, which will indicate improved and/or additive clinical value in monitoring the treatment response of prostate cancer, can be added to the panel of tests as they become available. Computer-assisted statistical techniques, e.g. the Cox model and logistic model, among others, will be used for systematic and objective clinical-laboratory analysis. Additionally, establishment and inventory of a serum bank of prostate cancer will be carefully maintained and further expanded. This serum bank represents a national resource. The purpose of this renewal proposal is to continue the core function of this central laboratory, which has been a major component and has played as essential role in the continued success of the major cooperative clinical trial on prostate cancer under the auspices of the National Cancer Institute.

该提案的目的是继续提供研究和 国家临床合作试验实验室核心支持 癌症研究所的国家前列腺癌项目。 出于以下目的 质量控制，各参与中心势在必行 具有统一的生物标志物，与监测疗效相关 前列腺癌的治疗和管理，采用各种治疗方案。 可以有效地进行客观的临床病理评价 在一个合作小组中，仅来自一组标准的测试和数据。 这 评估将根据在医院收集的临床信息进行 该集团中央统计局，并从多个实验室测试， 根据本提案的规定，这些内容在 当地或常规参与医院。 血清前列腺特异性 抗原、前列腺酸性磷酸酶、骨同工酶和肝同工酶 将测量碱性磷酸酶。 任何新的生物标志物或检测方法 程序，这将表明改善和/或附加的临床价值 监测前列腺癌的治疗反应，可以添加到 测试小组可用时。 计算机辅助统计 技术，例如Cox 模型和 Logistic 模型等将是 用于系统和客观的临床实验室分析。 此外，前列腺血清库的建立和库存 癌症将被精心维护并进一步扩大。 这个血清库 代表国家资源。 本次更新提案的目的是 继续该中心实验室的核心功能 主要组成部分，并在持续成功中发挥了至关重要的作用 前列腺癌重大合作临床试验 国家癌症研究所的赞助。